Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Defining the Pathways of Metastasis in Group 3 and Group 4 Medulloblastoma
FY 2016-17
Summary
Medulloblastoma is the most common type of malignant brain cancer in children. Through many years of focused study, scientists have learned a considerable amount about the cellular events that cause this type of cancer to develop into a tumour. What remains a mystery is how cells from this tumour gain the ability to detach, enter circulation, and travel to all regions of the body. Since so little is known about this complex process, known as metastasis, the only therapies available to treat metastases are those for primary tumours. While these treatment regimens are very successful at attacking primary tumours, they are much less effective at eliminating metastases. As such, it is time to map out, once and for all, the detailed cellular mechanisms which are enabling Medulloblastoma to metastasize. In the laboratory of scientist and neurosurgeon Dr. Michael Taylor at the Hospital for Sick Children in Toronto, I am profiling the activity of genes across the genome in primary tumours and spine metastases. I already have preliminary evidence showing that single genes, and groups of interdependent genes are more active in metastases than in primary tumours, suggesting that they may play an indispensable part in the spreading of cancer. I have just begun another study of gene activity in the subpopulation of primary tumour cells that metastasize. The results of this groundbreaking study will enable doctors to predict if a primary tumour can be metastatic. This will, for the first time, make it possible to tailor therapy to the precise genetics of the tumour in each patient. With this degree of specificity, these personalized treatment regimens will be significantly more effective, and safer than what is available today. For the sake of the courageous children who are forced to live with both the symptoms of their cancer, and the damage caused by their therapy, it is time to acquire the knowledge that will be necessary to find a better way.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
362472
Name
Matan-Lithwick Stuart A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Defining the Pathways of Metastasis in Group 3 and Group 4 Medulloblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Cancer; Cerebellum; Diagnostics; Differential Expression; Genetics; Medulloblastoma; Metastasis; Paediatrics; Personalized Medicine
Abstract
Medulloblastoma is the most common type of malignant brain cancer in children. Through many years of focused study, scientists have learned a considerable amount about the cellular events that cause this type of cancer to develop into a tumour. What remains a mystery is how cells from this tumour gain the ability to detach, enter circulation, and travel to all regions of the body. Since so little is known about this complex process, known as metastasis, the only therapies available to treat metastases are those for primary tumours. While these treatment regimens are very successful at attacking primary tumours, they are much less effective at eliminating metastases. As such, it is time to map out, once and for all, the detailed cellular mechanisms which are enabling Medulloblastoma to metastasize. In the laboratory of scientist and neurosurgeon Dr. Michael Taylor at the Hospital for Sick Children in Toronto, I am profiling the activity of genes across the genome in primary tumours and spine metastases. I already have preliminary evidence showing that single genes, and groups of interdependent genes are more active in metastases than in primary tumours, suggesting that they may play an indispensable part in the spreading of cancer. I have just begun another study of gene activity in the subpopulation of primary tumour cells that metastasize. The results of this groundbreaking study will enable doctors to predict if a primary tumour can be metastatic. This will, for the first time, make it possible to tailor therapy to the precise genetics of the tumour in each patient. With this degree of specificity, these personalized treatment regimens will be significantly more effective, and safer than what is available today. For the sake of the courageous children who are forced to live with both the symptoms of their cancer, and the damage caused by their therapy, it is time to acquire the knowledge that will be necessary to find a better way.
Competitiondate
201611
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Matan-Lithwick, Stuart A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~